EUVIMED · CrossrefJournal
Journal of Medicinal Chemistry
ISSN 0022-2623 · American Chemical Society (ACS)
Latest articles
Discovery of Potent and Selective Quinazoline-Based LATS1/2 Inhibitors Promoting Hepatic Regeneration
Development of Second Generation Thieno[2,3- d ]pyrimidin-4-one Derivatives as Positive Allosteric Modulators of the N -Methyl- d -Aspartate Receptor
Isotopic Labeling of the Tyrosine Kinase Inhibitor Binimetinib with Fluorine-18 and Preclinical Evaluation
What Does Generalizable AI in Drug Discovery Really Mean?
Toward Distributed Robustness in Resistance-Aware Lead Optimization
Discovery of an RNF126-Dependent Polθ Degrader Exhibiting In Vivo Activity in an HR-Deficient Tumor Model
Scaffold Hopping from Quinazoline to Tetrahydropyrido[3,4- d ]pyrimidine: Enhancing the Potency and Selectivity of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
Correction to: “Three Nitrogen Atoms Turn Old Kinase Inhibitors into New Targetable Remedy”
ATTEC-Based Autophagic Elimination of HBV Core Protein Achieves Potent Viral Suppression
Novel Spiroisatin Derivatives Potentially Useful for Preventing Myocardial Reperfusion Injury
Selective XPO1/CRM1 Inhibitor Verdinexor (KPT-335): The First and Only Oral Treatment Fully Approved by the U.S. FDA for Canine Lymphoma
Defining the Diphyllin Pharmacophore for Broad-Spectrum Antiviral V-ATPase Inhibition by Structure-Guided Scaffold Modifications
Discovery and Preclinical Characterization of Benzofuran Derivatives as Potent, Selective, and Orally Bioavailable GSPT1 Molecular Glue Degraders for the Treatment of MYC-Driven Cancers
Ubiquitination-Informed Reinforcement Learning Linker Generator Enables Discovery of Novel FGFR4 PROTAC Degraders
Engineering Camptothecin Prodrugs for Cancer Therapy: An Exposure-First Perspective
A Novel Mathematical Model for Predicting the Agonist Activity of Mixtures Containing Agonist and Antagonist Ligands in Drug Discovery Screening
Photoswitchable Inhibitors Targeting the Glucose Transporter GLUT1
Photoactivatable Small-Molecule PD-L1 Inhibitors for Checkpoint Blockade-based Tumor Immunotherapy
Lung-Tailored Pyrrolo-pyrimidine DDR Inhibitors Designed for Optimized Local Delivery
Cascade Mono- and Di-Functionalization of Anticancer Diastereomeric Benzoxazole-Ansamycins toward the Development of Highly Potent Hsp90 Inhibitors of Decreased Toxicity in Normal Cells
Alpha-Lipoic Acid Derivatives: A Multifunctional Neuroprotective Agent with Potential for Treating Ischemic Stroke
Democratizing Drug Discovery: A Scalable Open-Source Pipeline for Massive Specific Protein Target QSAR Modeling Using ChEMBL
Discovery of Orally Effective Corydamine Derivatives Targeting Glutathione Metabolism to Sensitize Hepatocellular Carcinoma to Sorafenib
Nucleic Acid Aptamers in Bacteriology: Mapping the Landscape, Exploring Bioimaging Applications, Challenges, and Future Perspectives
Development of a Potent and Isoform-Selective HDAC11 Inhibitor with Anti-Tumor Efficacy against Non-Small Cell Lung Cancer
Discovery of Potent and Non-cytotoxic HDAC3-Selective Degraders Featuring a Propyl Hydrazide Zinc-Binding Group
From Ubiquitination to Proteasome-Directed Recruiting: Emerging Mechanisms and Therapeutic Potential in Targeted Protein Degradation
A Portable N-Terminal Biphenyl Motif in LL-37 Enhances the Activity of Short Human Cathelicidin Derivatives
Triskellines A (3,6,8-Trisubstituted [1,2,4]triazolo[4,3- b ]pyridazines) as Potent Antagonists of Human Adenosine Receptor A3
Centromere-Targeting Chimeras for Combating Cancer Drug Resistance
Volumes
2026 · 1,5002025 · 1,5672024 · 1,2862023 · 1,0292022 · 9752021 · 1,0682020 · 9732019 · 7722018 · 7972017 · 7562016 · 8372015 · 7592014 · 8362013 · 8232012 · 9252011 · 7412010 · 8182009 · 8712008 · 9272007 · 7672006 · 9242005 · 9322004 · 7812003 · 6502002 · 6662001 · 5332000 · 5761999 · 6081998 · 6341997 · 5721996 · 7371995 · 6211994 · 6121993 · 6031992 · 6851991 · 5211990 · 5331989 · 4361988 · 4141987 · 428
EUVIMED